ArticleFolia microbiologica2026
Unveiling a sustainable approach to cancer treatment: the antitumor activity of amygdalin and cell-free supernatant of Lacticaseibacillus rhamnosus.
Article in Folia microbiologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The pharmaceutical industry increasingly prioritizes environmental sustainability across its strategies, focusing on developing eco-friendly anti-cancer treatments. This is particularly important considering many anti-cancer drugs are not fully metabolized and pollute aquatic ecosystems. Amygdalin, a plant-derived compound, and cell-free supernatants (CFS) of Lacticaseibacillus rhamnosus show promise as sustainable anti-cancer agents. This study evaluated the potential anti-cancer activity of amygdalin and L. rhamnosus CFS against MCF-7 and A549 cancer cell lines. Cell viability was assessed using the MTT assay in response to monotherapy and combination therapy treatments. The induction of apoptosis was investigated using flow cytometric analyses. The combination demonstrated a synergistic effect on MCF-7 and A549 cell lines, with a combination index (CI) value of 0.8159 ± 0.0245 and 0.6422 ± 0.0316, respectively. Further analysis using propidium iodide (PI) staining and Annexin V confirmed increased apoptosis in combination-treated cells compared to those treated with amygdalin alone. These findings suggest that the combination of amygdalin and CFS of L. rhamnosus exhibits a synergistic anti-cancer effect against MCF-7 and A549 cells. Therefore, this combination is considered sustainable, eco-friendly, and effective anti-cancer treatment. This is the first study to investigate the anti-cancer effect of amygdalin in combination with L. rhamnosus cell-free supernatant (CFS) while considering its potential for environmental sustainability. Further research in a xenograft animal model is warranted to validate these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.